Assessment of Ki67 immunohistochemical expression as a prognostic marker in breast carcinoma

Volkova L.V., Paramzin F.N., Pashov A.I., Musatov A.A., Ashrafyan L.A.

1) Immanuel Kant Baltic Federal University, Kaliningrad, Russia; 2) Central City Clinical Hospital, Kaliningrad, Russia; 3) V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology of Minzdrav of Russia, Moscow. Russia
Aim. To compare Ki-67 proliferation marker expression in unspecified type of breast cancer determined by traditional visual assessment and digital microscopy using PatternQuant software (QuantCenter 3DHISTECH).
Material and methods. A comparative study including 50 patients with unspecified type of breast cancer was conducted to compare the determination of the Ki-67 proliferation marker by a pathologist using the traditional visual quantitative assessment and by digital microscopy using PatternQuant software (QuantCenter 3DHISTECH).
Results. Despite comparable mean Ki-67 expressions, their maximum and minimum values determined by a pathologist were slightly higher than by automated assessment. This is especially important in determining a threshold for Ki-67 expression (14%) in each individual case to distinguish molecular subtypes of breast cancer.
Conclusion To objectify the quantitative assessment, a further standardized examination of breast cancer proliferation markers is recommended, especially in cases of significant tumor heterogeneity.


breast cancer
Ki-67 proliferation marker
digital microscopy


  1. Каприн А.Д., Старинский В.В., Петрова Г.В. Состояние онкологической помощи населению России в 2018 году. М.: ФГБУ «МНИОИ им. ПА Герцена» – филиал ФГБУ «НМИЦ радиологии» Минздрава России. 2019. 30c. [Kaprin A.D., Starinsky V.V., Petrova G.V. Status of cancer care for the population of Russia in 2018. Moscow: P. Herzen Moscow Oncology Research Institute–Branch of FSBI NMRRC of the Ministry of Health of the Russian Federation, 2019: 30 p. (in Russian)].
  2. Penault-Llorca F., Radosevic-Robin N. Ki67 assessment in breast cancer: an update.Pathology. 2017; 49(2): 166–71. doi: 10.1016/j.pathol.2016.11.006
  3. Jing N., Fang C., Williams D.S. Validity and reliability of Ki-67 assessment in oestrogen receptor positive breast cancer. Pathology. 2017; 49(4): 371–8. doi: 10.1016/j.pathol.2017.02.001.
  4. Rakha E.A., Green A.R. Molecular classification of breast cancer: what the pathologist needs to know. Pathology. 2017; 49(2): 111–9. doi: 10.1016/j.pathol.2016.10.012.
  5. Harvey J., Thomas C., Wood B., Hardie M., Dessauvagie B., Combrinck M., Frost F.A., Sterrett G. Practical issues concerning the implementation of Ki-67 proliferative index measurement in breast cancer reporting. Pathology. 2015; 47(1): 13–20. doi: 10.1097/PAT.0000000000000192.
  6. Кушнарев В.А., Артемьева Е.С., Кудайбергенова А.Г. Сравнение цифрового и визуального методов для оценки индекса Ki-67 в инвазивных карциномах молочной железы. Архив патологии. 2018; 80(2): 38–42.[Kushnarev V.A., Artemyeva A.C., Kudaybergenova A.G. Comparison of digital and visual methods for Ki-67 assessment in invasive breast carcinomas. Archive of Pathology = Arkhiv Patologii. 2018; 80(2): 38–42. (in Russian)]. doi:10.17116/patol201880238-42
  7. Elmore J.G., Nelson H.D., Pepe M.S., Longton G.M., Tosteson A.N., Geller B., Onega T., Carney P.A., Jackson S.L., Allison K.H., Weaver D.L. Variability in pathologists’ interpretations of individual breast biopsy slides: a population perspective. Ann Intern Med. 2016; 164(10): 649–55. doi: 10.7326/M15-0964.
  8. Williams B.J., Hanby A., Millican-Slater R., Nijhawan A., Verghese E., Treanor D. Digital pathology for the primary diagnosis of breast histopathological specimens: an innovative validation and concordance study on digital pathology validation and training. Histopathology. 2018; 72(4): 662–71. doi: 10.1111/his.13403.
  9. Del Rosario Taco Sanchez M., Soler-Monsó T., Petit A., Azcarate J., Lasheras A., Artal C., Gil M., Falo C., Pla M.J., Matias-Guiu X. Digital quantification of KI-67 in breast cancer. Virchows Archiv. 2019; 474(2): 169–76. doi: 10.1007/s00428-018-2481-3.
  10. Elmore J.G., Longton G.M., Pepe M.S., Carney P.A, Nelson H.D., Allison K.H., Geller B.M., Onega T., Tosteson A.N., Mercan E., Shapiro L.G., Brunyé T.T., Morgan T.R., Weaver D.L. A randomized study comparing digital imaging to traditional glass slide microscopy for breast biopsy and cancer diagnosis. J Pathol Inform. 2017; 8:12. doi: 10.4103/2153-3539.201920.
  11. Joshi S., Watkins J., Gazinska P., et al. Digital imaging in the immunohistochemical evaluation of the proliferation markers Ki67, MCM2 and Geminin, in early breast cancer, and their putative prognostic value. BMC Cancer. 2015; 15: 546. doi:10.1186/s12885-015-1531-3
  12. Menter D.G., Hoque A., Motiwala N., Sahin A.A., Sneige N., Lieberman R., Lippman S.M. Computerized image analysis of Ki-67 in ductal breast carcinoma in situ. Anal Quant Cytol Histol. 2001; 23(3): 218–28. PMID: 11444192
  13. Прилепская Е.А., и др. Возможности автоматизированного анализа изображений в патологии. Архив патологии. 2016; 78(1): 51–5. [Prilepskaya E.A., et al. Possibilities of automated image analysis in pathology. Archive of Pathology = Arkhiv Patologii. 2016; 78 (1): 51–5. (in Russian)] 10.17116/patol201678151-55
  14. Zhong F., Bi R., Yu B., Yang F., Yang W., Shui R. A comparison of visual assessment and automated digital image analysis of Ki67 labeling index in breast cancer. PloS one. 2016; 11(2): e0150505. doi: 10.1371/journal.pone.0150505
  15. Varga Z., Cassoly E., Li Q., Oehlschlegel C., Tapia C., Lehr H.A., Klingbiel D., Thürlimann B., Ruhstaller T. Standardization for Ki-67 assessment in moderately differentiated breast cancer. A retrospective analysis of the SAKK 28/12 study. PLoS One. 2015; 10(4): e0123435. doi: 10.1371/journal.pone.0123435
  16. Plancoulaine B., Laurinaviciene A., Herlin P., Besusparis J., Meskauskas R., Baltrusaityte I., Iqbal Y., Laurinavicius A. A methodology for comprehensive breast cancer Ki67 labeling index with intra-tumor heterogeneity appraisal based on hexagonal tiling of digital image analysis data. Virchows Archiv. 2015; 467(6): 711–22. doi: 10.1007/s00428-015-1865-x
  17. Rakha E.A., Aleskandarani M., Toss M.S., et al. Breast cancer histologic grading using digital microscopy: concordance and outcome association. Journal of clinical pathology. 2018; 71(8): 680–6. doi:10.1136/jclinpath-2017-204979

Received 23.12.2019

Accepted 26.12.2019

About the Authors

Larisa V. Volkova, MD, PhD, Professor, Head of the Department of Laboratory Diagnostics of Clinical Diagnostical Centre, Professor of the Department of Fundamental Medicine of Medical Institute, Immanuel Kant Baltic Federal University. Phone: +7(921)852-2042; e-mail:
Address: 14 Alexander Nevsky Str., 236016, Kaliningrad, Russia;
Fedor N. Paramzin, surgeon-oncologist, “Central City Clinical Hospital”. Phone: +7 (4012)64-78-21; e-mail:
Address: 3 Letnya Str., 236005, Kaliningrad, Russia;
Aleksander I. Pashov, MD, Head of the Department of Obstetrics and Gynecology, Immanuel Kant Baltic Federal University.
Phone  +7(911)-461-49-98; email:
Address: 14 Alexander Nevsky Str., 236016, Kaliningrad, Russia;
Aleksey A. Musatov, Clinical Ordinator of the Medical Institute, Immanuel Kant Baltic Federal University. Phone: + 7(911)453-64-06; e-mail:
Address: 14 Alexander Nevsky Str., 236016, Kaliningrad, Russia, 236016.
Lev A. Ashrafyan, acad. of RAS, MD, Professor, deputy director of FSBI «National medical research center for obstetrics, gynecology and perinatology named
after academician V.I. Kulakov» ministry of healthcare of the Russian Federation. Phone: +7(095)531-44-44 е-mail:
Address: 4, Oparina street, Moscow, Russian Federation, 117997.

For citation: Volkova L.V., Paramzin F.N., Pashov A.I., Musatov A.A., Ashrafyan L.A. Assessment of Ki67 immunohistochemical expression as a prognostic marker in breast carcinoma.
Akusherstvo i Ginekologiya/Obstetrics and Gynecology. 2020; 1 (Suppl): 81-5. (in Russian)

Similar Articles

By continuing to use our site, you consent to the processing of cookies that ensure the proper functioning of the site.